Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 20Prostatic Neoplasms 19Glioblastoma 18Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 15Lung Neoplasms 12Rectal Neoplasms 11Oropharyngeal Neoplasms 10Neoplasms 9Head and Neck Neoplasms 8Glioma 8Astrocytoma 8Neoplasm Metastasis 7Sarcoma 6Esophageal Neoplasms 6Carcinoma, Squamous Cell 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Lymphoma, Follicular 5Hodgkin Disease 5Gliosarcoma 5Esophageal Squamous Cell Carcinoma 5Carcinoma 5Burkitt Lymphoma 5Brain Neoplasms 5Adenocarcinoma of Lung 5Adenocarcinoma Of Esophagus 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Nasopharyngeal Carcinoma 4

Interventions

relugolix 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Specimen Handling 2Radiotherapy 2Radiation 2Magnetic Resonance Spectroscopy 2Leuprolide 2Goserelin 2Biopsy 2radium Ra 223 dichloride 1luprolide acetate gel depot 1histrelin 1gallium 68 PSMA-11 1enzalutamide 1darolutamide 1bicalutamide 1Triptorelin Pamoate 1Surgical Procedures, Operative 1Salicylic Acid 1Radiotherapy, Image-Guided 1Radiosurgery 1Radiation Dose Hypofractionation 1Flutamide 1Buserelin 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostate Adenocarcinoma × Radiotherapy × 90 days × Clear all
NCT03274687 2026-05-20

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

NRG Oncology

Phase 3 Completed
296 enrolled 29 charts
Genitourinary

Prostate Adenocarcinoma

NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡